Mistral Continuous (Dienogest, Ethinylestradiol | Lactose)

Dienogest, the active ingredient in Mistral Continuous, is a combined oral contraceptive presented as a tablet for oral use. It works together with ethinylestradiol to prevent pregnancy and to help regulate menstrual cycles in women of reproductive age, and is indicated for contraception and menstrual cycle regulation.

GNH USA supplies Mistral Continuous as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, providing reliable access to quality‑assured medicines through established distribution networks and compliance with global regulatory standards.

Mistral Continuous, a combined oral contraceptive, acts within the hormonal contraception pathway to prevent pregnancy and manage menstrual disorders. - Contraception: prevents pregnancy by suppressing ovulation, thickening cervical mucus and altering the endometrial lining. - Menstrual cycle regulation: reduces irregular bleeding and stabilizes cycle length for women with dysfunctional uterine bleeding. - Hormonal acne treatment: may improve acne associated with androgen excess by providing anti‑androgenic progestogen activity.

Mistral Continuous may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: transient cranial pain. - Breakthrough bleeding: spotting between periods. - Weight gain: slight increase in body weight. - Mood changes: irritability or mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new or worsening high blood pressure. - Liver dysfunction: jaundice or abnormal liver enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Depression: severe mood disorder requiring medical attention.

Before prescribing Mistral Continuous, clinicians should consider several precautionary measures to ensure patient safety. - Contraindications: known thrombophilia, estrogen‑dependent tumor, active liver disease, pregnancy or breastfeeding. - Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction before initiation. - Drug interactions: review concomitant medications that may affect hormone levels. - Monitoring: periodic evaluation of blood pressure and menstrual pattern is recommended. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Mistral Continuous can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): combined use may increase risk of thrombotic events. - Selective estrogen receptor modulators: may interfere with hormonal balance.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole, itraconazole): can increase plasma hormone concentrations. - Herbal supplements (e.g., St John’s wort): may decrease contraceptive effectiveness. - Certain antibiotics (e.g., tetracycline, metronidazole): potential modest reduction in efficacy; monitor for breakthrough bleeding.